Insmed to host investor call to discuss topline results from phase 3 aspen study of brensocatib in patients with bronchiectasis

—conference call to take place tomorrow, tuesday, may 28, 2024, at 8:00 am et— bridgewater, n.j. , may 27, 2024 /prnewswire/ -- insmed incorporated (nasdaq: insm), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will host a conference call and webcast tomorrow, tuesday, may 28, 2024, at 8:00 am et to discuss topline results from the aspen study, a global, randomized, double-blind, placebo-controlled phase 3 study to assess the efficacy, safety, and tolerability of brensocatib in patients with non-cystic fibrosis bronchiectasis.
INSM Ratings Summary
INSM Quant Ranking